ArticleBlood2020
HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern.
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Perceptions of donor screening-Do I always need to tell the truth?Transfusion medicine (Oxford, England) · 2026Article
- The future of transfusion and transplant microbiology safety: can new molecular technologies improve the safety of blood and transplant?BMC infectious diseases · 2026Review
- HIV serologic reactivity varies with time of ART initiation in persons on long-term ART.Journal of clinical microbiology · 2026Article
- Article
- Compound adsorption device in pathogen reduction technology removes multiple drugs from plasma components.Transfusion · 2026Article
- A preliminary survey on the use of ART among blood donors in Shenzhen China and its implications to blood safety.BMC infectious diseases · 2025Article
- Compliance with gender-neutral sexual behavior-based blood donor screening questions.Transfusion · 2025Article
- Improved HIV-1 RNA detection using whole blood versus plasma in antiretroviral-treated individuals.Journal of clinical microbiology · 2025Article
- Urban versus rural blood donors in the United States and the relationship with transfusion-transmissible infections.Transfusion · 2025Article
- Article
- Monitoring HIV Antiretroviral Therapy via Aptamer-Based Measurements in Preclinical Animal Models, in Human Plasma.Advanced sensor research · 2025Article
- Suppressed HIV antibody responses following exposure to antiretrovirals-evidence from PrEP randomized trials and early antiretroviral treatment initiation studies.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
- HIV Subtypes and Drug-resistance-associated Mutations in US Blood Donors, 2015-2020.Open forum infectious diseases · 2024Article
- The impact of non-disclosure of HIV status and antiretroviral therapy on HIV recency testing and incidence algorithms.Vox sanguinis · 2024Article
- Article
- Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion-Transmitted and Emerging Infectious Diseases.Transfusion medicine reviews · 2023Article
- Motivations for blood donation by HIV-positive individuals on antiretrovirals in South Africa: A qualitative study.Transfusion medicine (Oxford, England) · 2023Article
- Perceived risk of HIV transmission by blood transfusion among gay, bisexual, and other men who have sex with men (gbMSM) in Australia.Transfusion · 2023Article
- Article
- Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 14 institutions in 1 country.
Funding
Abstract
Antiretroviral therapy (ART) to treat and pre-exposure prophylaxis (PrEP) to prevent HIV infection are effective tools to help end the HIV epidemic. However, their use could affect HIV transfusion-transmission risk. Three different ART/PrEP prevalence analyses in blood donors were conducted. First, blood samples from HIV-positive and a comparison group of infection-nonreactive donors were tested under blind using liquid chromatography-tandem mass spectrometry for ART. Second, blood donor samples from infection-nonreactive, 18- to 45-year-old, male, first-time blood donors in 6 US locations were tested for emtricitabine and tenofovir. Third, in men who have sex with men (MSM) participating in the 2017 Centers for Disease Control and Prevention National HIV Behavioral Surveillance (NHBS) from 5 US cities, self-reported PrEP use proximate to donation was assessed. In blind testing, no ART was detected in 300 infection-nonreactive donor samples, but in 299 HIV confirmed-infected donor samples, 46 (15.4%; 95% confidence interval [CI], 11.5% to 20.0%) had evidence of ART. Of the 1494 samples tested from first-time male donors, 9 (0.6%; 95% CI, 0.03% to 1.1%) had tenofovir and emtricitabine. In the NHBS MSM survey, 27 of 591 respondents (4.8%; 95% CI, 3.2% to 6.9%) reported donating blood in 2016 or 2017 and PrEP use within the same time frame as blood donation. Persons who are HIV positive and taking ART and persons taking PrEP to prevent HIV infection are donating blood. Both situations could lead to increased risk of HIV transfusion transmission if blood screening assays are unable to detect HIV in donations from infected donors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.